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OBJECTIVE — Littleisknownabouttheprevalenceof-cellautoantibodiesinchildrenwith
excess body weight. The prevalence of type 1 diabetes autoantibodies and its relation with
hyperglycemia was analyzed in 686 overweight/obese children and adolescents.
RESEARCH DESIGN AND METHODS — All children underwent an oral glucose
tolerance test, and anti-GAD, anti-IA2, and anti-IAA autoantibodies were measured. Autoanti-
body prevalence was evaluated in 107 normal-weight children for comparison.
RESULTS — A single autoantibody was present in 2.18% of overweight/obese subjects and
1.86%normal-weightsubjects(PNS).Postloadglycemiawassigniﬁcantlyhigherinantibody-
positive children (133  69.9 vs. 105.4  17.7 mg/dl, P  0.0001) compared with autoanti-
body-negative subjects. No difference in autoantibody distribution was seen when our cohort
was stratiﬁed by age, sex, SDS-BMI, pubertal stage, and homeostasis model assessment–insulin
resistance (HOMA-IR).
CONCLUSIONS — The2.18%prevalenceoftype1diabetesautoantibodiesissimilartothat
reported in nonobese children. This study provided evidence that excess body weight and
insulin resistance do not inﬂuence autoantibody frequency.
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O
ver the last 60 years, a striking in-
creaseintheincidenceofchildhood
type 1 diabetes has been observed
consistently in almost all populations.
EURODIAB (1) reported an overall in-
crease of 3.2% per annum in Europe be-
tween 1989 and 1998. There have also
been considerable changes in childhood
nutrition, which have resulted in changes
in growth. Increased weight, height, and
BMI in children have all been associated
with a higher risk of type 1 diabetes (2).
The so-called “accelerator hypothesis” ar-
gues that obesity causing overworked
-cells underlies both type 1 and type 2
diabetes and that these “types” are only
distinguished by how the body responds
to this growth-induced -cell stress. This
hypothesis therefore attributes the rise in
type1diabetestoanincreaseinchildobe-
sity (3). A variation of the hypothesis
suggests that, once initiated, islet autoim-
munity progresses more rapidly in the
context of “overload” of the -cells due to
increased insulin resistance (4).
Sardinia has one of the highest inci-
dences of type 1 diabetes worldwide, sec-
ond only to Finland (5). Moreover,
Sardinian children and adolescents are
experiencing the same increase in obesity
as other European populations (6). To
date, little is known on the prevalence of
autoantibodies against -cells in children
with excess body weight.
The aim of our study was to analyze
the prevalence of type 1 diabetes autoan-
tibodies in a cohort of Sardinian over-
weight/obese children and adolescents
and to evaluate their distribution in
relation to the presence of glucose
abnormalities.
RESEARCH DESIGN AND
METHODS— A total of 686 over-
weight/obese Italian children and adoles-
cents were studied, all attending the
PediatricEndocrineUnitforthepresence,
in all cases, of excess body weight. Exclu-
sion criteria were the presence of endo-
crine disorders or genetic syndromes,
including syndromic obesity. A second
group of normal-weight children (n 
107) was collected for antibody preva-
lence comparison. Clinical characteristics
of all 793 subjects are shown in Table 1.
Clinical and metabolic parameters
All overweight/obese subjects underwent
an oral glucose tolerance test (OGTT).
The OGTT was performed according to
clinical recommendations for children
(1.75 g/kg body wt, up to 75 g). Plasma
glucose and insulin were measured at 0
and 120 min. Subjects were classiﬁed ac-
cordingtoAmericanDiabetesAssociation
criteria in subjects with normal glucose
tolerance, with impaired fasting glycemia
(IFG), impaired glucose tolerance (IGT),
or diabetes. Impaired glucose regulation
(IGR) deﬁned the presence of any cate-
gory of glucose abnormality (IFG, IGT,
and diabetes). Diagnosis of type 1 diabe-
tes was made in the presence of diabetic
hyperglycemia and at least one -cell
autoantibody.
Inall793children,anti-GAD,anti-IA2,
and anti-IAA autoantibodies (GAD-Ab
125I-
Radioassay, IA2-Ab
125I-Radioassay, and
IAA-Ab
125I-Radioassay) were assessed (all
from DLD Diagnostika, Germany). The up-
per normal limit for anti-GAD and anti-IA2
is 1 unit/ml and for anti-IAA is 0.4
units/ml.Anti-GADassayhasanintra-assay
coefﬁcient of variation (CV) of 3.6% and an
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IA2 assay has intra- and interassay CVs be-
tween 2.5 and 2.8% and between 3.3 and
5.3%, respectively. Anti-IAA assay has in-
tra- and interassay CVs between 3.0 and
5.8% and 4.2 and 6.7%, respectively.
Our laboratory achieved 76% sensitiv-
ity and 95.7% speciﬁcity for anti-GAD and
64% sensitivity and 98.9% speciﬁcity for
anti-IA2 at the latest Diabetes Antibody
Standardization Program (DASP2009). An-
ti-IAA results were conﬁrmed by a second
method based on a competitive ﬂuid-phase
radioimmunoassay (7).
RESULTS
Type 1 diabetes autoantibodies
In the 686 overweight/obese children, a
singleautoantibody(eitheranti-GAD,an-
ti-IA2,oranti-IAA)waspresentin15sub-
jects(2.18%).Anti-GADsweredetectable
in 13 of 686 (1.89%) children, anti-IA2s
were present in 6 of 686 (0.87%) chil-
dren, and anti-IAAs were found in 3 of
686 (0.43%) children. Two antibodies
were found together in ﬁve (0.7%) sub-
jects. All three autoantibodies were found
in only one subject. In the 107 normal-
weight children, anti-GAD and anti-IA2
were found together in two subjects
(1.86%, P  NS vs. overweight/obese
children).
No difference in autoantibody distri-
bution was observed when our cohort
was stratiﬁed by age, sex, SDS-BMI, pu-
bertal stage, and the homeostasis model
assessment–insulin resistance (HOMA- IR)
(data not shown).
IGR and autoantibodies in
overweight/obese children
OverallprevalenceofIGRinourcohortof
overweight/obese children was 11.37%
(78/686). The frequency of IFG was
8.16% (56/686), IGT 3.2% (22/686), and
diabetes 0.6% (4/686).
When divided on the basis of glucose
regulation, the presence of autoimmunity
was three times more prevalent in chil-
dren with IGR (5.12%) than in children
with normal glucose tolerance (1.80%).
The prevalence of glucose abnormalities
in antibody-positive subjects was 27%,
compared with 11% in antibody-negative
children.
In the whole group, anti-IAA titers
correlated with postload glycemia (P 
0.03), which was signiﬁcantly higher in
antibody-positive children (133  69.9
vs. 105.4  17.7 mg/dl; P  0.0001)
when compared with antibody-negative
subjects.Antibodiestiterswerenotcorre-
lated to fasting glucose (93.5  16.2 vs.
89.6  7.4; P  NS).
CONCLUSIONS — In the present
study, we found that the prevalence of
autoantibodies in overweight/obese chil-
dren was similar (2.18%) to that found in
our cohort of normal-weight–matched
subjects (1.86%, P  NS), as well as to
that reported in the general population of
schoolchildren (8,9). When our cohort
was stratiﬁed in subjects with normal and
impaired glucose regulation, prevalence
of autoantibodies was higher in individu-
als with IGR (5.12%). This prevalence is
similar to that reported in nonobese hy-
perglycemic children (10).
We also found that antibody-positive
subjects had a signiﬁcantly higher 2-h
glycemia. Our results are in line with
thoserecentlydemonstratedintheDiabe-
tes Prevention Trial–Type 1 (DPT-1)
study (11), where the majority of subjects
diagnosed with type 1 diabetes had im-
paired post-OGTT glucose levels, thus
suggesting that OGTT in antibody-
positive subjects may help to prevent
acute-onset disease. With regards to this
point, the prevalence of glucose abnor-
malities in our antibody-positive subjects
was nearly 30%, and in all cases, IGR was
diagnosed by the 2-h value.
In conclusion, this study provides ev-
idence that excess body weight and insu-
lin resistance do not inﬂuence the
frequencies of autoantibodies as postu-
Table 1—Clinical and biochemical characteristics of overweight/obese and normal-weight children and adolescents
Overweight Obese
P (overweight
vs. obese)
Overweight/
obese Normal weight
P (overweight/
obese vs. normal
weight)
n 217 469 686 107
Age (years) 10.6  3 10.2  3.2 NS 10.3  3.2 11.4  3.2 0.01
Sex (F/M) (n) 124/93 236/233 NS 360/326 49/58 NS
Prepubertal/pubertal (n) 150/67 329/240 NS 479/207 68/39 NS
BMI (kg/m
2) 25.1  2.3 28.9  4 0.0001 27.7  4.5 17.9  2.7 0.0001
SDS-BMI 1.9  0.7 3.2  1.2 0.0001 2.8  1.2 -0.46  0.8 0.0001
Systolic blood pressure (mmHg) 104.19  13.4 107.53  15.5 0.017 106.4  14.9 105  10.6 NS
Diastolic blood pressure (mmHg) 61.35  7.9 62.38  9.4 NS 62  9 61.1  5.4 NS
Glycemia 0 (mg/dl) 90.1  7.8 89.4  7.6 NS 89.6  7.7 88.4  8.4 NS
Insulin (U/ml) 15.7  7.2 16.9  9.7 NS 16.6  9 11.7  6 0.0001
HOMA-IR 3.5  1.6 3.7  2.3 NS 3.7  2 2.6  1.4 0.0001
Total cholesterol (mg/dl) 168  34.1 165.9  32.2 NS 166.6  32.8 165  26.3 NS
HDL (mg/dl) 51.4  11.8 49.8  11 NS 50.3  11.3 59.4  12.2 0.0001
LDL (mg/dl) 105.1  28.9 103.3  28.2 NS 103.9  28.4 96.4  24 0.02
Triglycerides (mg/dl) 57.2  39.2 60.8  32.8 NS 59.7  35 45.7  29.5 0.0001
Autoantibody positive n (%) 7 (3.22) 8 (1.70) NS 15 (2.18) 2 (1.86) NS
Anti-GAD positive n (%) 6 (2.76) 7 (1.49) NS 13 (1.89) 2 (1.86) NS
Anti-IA2 positive n (%) 1 (0.46) 5 (1.06) NS 6 (0.87) 2 (1.86) NS
Anti-IAA positive n (%) 2 (0.92) 1 (0.21) NS 3 (0.43) 0 NS
DataaremeansSDunlessotherwiseindicated.Overweight,obesity,andSDS-BMIweredeﬁnedaccordingtoItaliangrowthchartsinpeopleaged2–20years(12).
1 SD of BMI deﬁnes overweight, 2 SD of BMI deﬁnes obesity. Pubertal developmental stages were determined according to Tanner. Differences between variables
were evaluated by two-tailed Student’s t test or Mann-Whitney test. Categorical variables were compared by 	
2 or Fischer’s exact tests.
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which is therefore not supported by our
data. It also shows that an obese child
can be at risk for type 1 diabetes as
much as a normal-weight child. How-
ever, the hypothesis of the “overload” of
-cells as a result of increased insulin
demandslinkedtoobesitywarrantsfur-
ther study.
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